US09058V1035 - Common Stock
BIOCRYST PHARMACEUTICALS INC
NASDAQ:BCRX (11/21/2024, 4:30:01 PM)
After market: 7.49 0 (0%)7.49
+0.19 (+2.6%)
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 536 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703
P: 19198591302
CEO: Jon P. Stonehouse
Employees: 536
Website: https://www.biocryst.com/
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services...
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to...
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BCRX earnings call for the period ending September 30, 2024.
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end...
Here you can normally see the latest stock twits on BCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: